2023-10-04-世界卫生组织-4._A_H3N2_-_Cell_culture-derived_-_Southern_Hemisphere_2024_2页_217kb

Influenza Vaccine Summary for 2024 Southern Hemisphere Season

• Vaccine Development: The 2024 southern hemisphere influenza vaccine targets the A(H3N2) lineage, using cell culture-derived candidate vaccine viruses (ccCVVs) or recombinant vaccine antigen(s).
• Virus Isolation and Testing: WHO Collaborating Centres (CCs) in the Global Influenza Surveillance and Response System (GISRS) isolate viruses using certified cell lines (e.g., MDCK 33016 PFa or NIID-MDCKb). Antigenic analysis and HI/VN tests confirm matching prototype viruses, but no other tests are conducted.
• Approval and Use: National or regional control authorities approve vaccine composition and manufacturing. Manufacturers must consult these authorities before using ccCVVs for production.
• Candidate Viruses:
  • Key ccCVVs: A/California/123/2022 (CVR-178*) and A/Sydney/1304/2022, isolated from cell lines like MDCK 33016 PF or developed by Seqirus.
  • Recommended for cccCVVs: Passage level and availability from sources like CDC (USA) or VIDRL (Australia).
  • Recombinant antigen sequence should closely match A/Massachusetts/18/2022 MDCK SIAT cell-derived.
• Reference Antigens and Reagents: Orderable from sources such as WHO Essential Regulatory Laboratories, with contact details listed.
• Guidelines: WHO recommendations and updates are available online for candidate vaccine viruses and potency testing reagents. For inquiries, contact gisrs-whohq@who.int.

For more details, refer to the provided WHO links.